S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
NASDAQ:IMCR

Immunocore (IMCR) Stock Price, News & Analysis

$56.53
-2.54 (-4.30%)
(As of 04/12/2024 ET)
Today's Range
$56.33
$59.07
50-Day Range
$56.53
$75.36
52-Week Range
$42.21
$76.98
Volume
358,753 shs
Average Volume
356,653 shs
Market Capitalization
$2.82 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$80.55

Immunocore MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
42.5% Upside
$80.55 Price Target
Short Interest
Bearish
9.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of Immunocore in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.54) to ($1.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.91 out of 5 stars

Medical Sector

635th out of 923 stocks

Biological Products, Except Diagnostic Industry

110th out of 155 stocks

IMCR stock logo

About Immunocore Stock (NASDAQ:IMCR)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

IMCR Stock Price History

IMCR Stock News Headlines

Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
IMCR Apr 2024 45.000 put
IMCR Apr 2024 95.000 call
Immunocore presented two posters at CROI 2024
Key Takeaways From Immunocore Hldgs Analyst Ratings
Immunocore FY 2023 Earnings Preview
Immunocore Holdings Ltd (IMCR)
See More Headlines
Receive IMCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/13/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IMCR
Fax
N/A
Employees
497
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$80.55
High Stock Price Target
$91.00
Low Stock Price Target
$63.00
Potential Upside/Downside
+42.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-55,290,000.00
Pretax Margin
-24.41%

Debt

Sales & Book Value

Annual Sales
$249.43 million
Book Value
$7.42 per share

Miscellaneous

Free Float
46,981,000
Market Cap
$2.82 billion
Optionable
Optionable
Beta
0.89
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Bahija Jallal Ph.D. (Age 63)
    CEO & Director
    Comp: $1.42M
  • Mr. Brian R. Di Donato M.B.A. (Age 57)
    CFO & Head of Strategy
  • Mr. John Trainer M.B.A. (Age 50)
    SVP & Chief Operating Officer
  • Mr. John Goll III
    SVP, Finance & Chief Accounting Officer
  • Ms. Annelise Vuidepot Ph.D.
    CTO and Head of Pipeline & Platform Research
  • Mr. Sean D. Buckley (Age 41)
    VP & Chief Information Officer
  • Clayton Robertson
    Head of Investor Relations
  • Ms. Lily Margaret Hepworth
    General Counsel & Company Secretary
  • Ms. Elizabeth Varki Jobes Esq. (Age 57)
    J.D., Chief Compliance Officer
  • Mr. Sébastien Desprez
    Head of Communications

IMCR Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunocore stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IMCR shares.
View IMCR analyst ratings
or view top-rated stocks.

What is Immunocore's stock price target for 2024?

12 equities research analysts have issued 1-year price objectives for Immunocore's stock. Their IMCR share price targets range from $63.00 to $91.00. On average, they anticipate the company's stock price to reach $80.55 in the next year. This suggests a possible upside of 42.5% from the stock's current price.
View analysts price targets for IMCR
or view top-rated stocks among Wall Street analysts.

How have IMCR shares performed in 2024?

Immunocore's stock was trading at $68.32 at the beginning of the year. Since then, IMCR shares have decreased by 17.3% and is now trading at $56.53.
View the best growth stocks for 2024 here
.

Are investors shorting Immunocore?

Immunocore saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,610,000 shares, an increase of 7.5% from the March 15th total of 4,290,000 shares. Based on an average daily trading volume, of 491,700 shares, the days-to-cover ratio is presently 9.4 days. Currently, 9.5% of the company's stock are short sold.
View Immunocore's Short Interest
.

When is Immunocore's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our IMCR earnings forecast
.

How were Immunocore's earnings last quarter?

Immunocore Holdings plc (NASDAQ:IMCR) posted its earnings results on Wednesday, February, 28th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.12. The company had revenue of $70.16 million for the quarter, compared to analyst estimates of $53.25 million. Immunocore had a negative trailing twelve-month return on equity of 15.78% and a negative net margin of 22.48%. The company's quarterly revenue was up 22.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.63) EPS.

What ETFs hold Immunocore's stock?
When did Immunocore IPO?

Immunocore (IMCR) raised $199 million in an initial public offering on Friday, February 5th 2021. The company issued 8,300,000 shares at a price of $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies served as the underwriters for the IPO.

How do I buy shares of Immunocore?

Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMCR) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners